Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amneal Pharmaceuticals Inc
(NQ:
AMRX
)
8.785
+0.005 (+0.06%)
Streaming Delayed Price
Updated: 10:12 AM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amneal Pharmaceuticals Inc
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
September 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
August 20, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Second Quarter 2024 Financial Results
August 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
August 07, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
July 29, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Second Quarter 2024 Results on August 9, 2024
July 11, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
July 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
July 01, 2024
From
Kashiv BioSciences, LLC
Via
Business Wire
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
July 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Releases 2023 Environmental, Social and Governance Report
June 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
June 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.